PAI-1 Signaling Pathway Assay (CAT#: STEM-MB-0375-WXH)

The PAI-1 signaling pathway plays an important role in regulating the LPS-induced inflammatory response in alveolar macrophages.PAI-1 signaling may promote the expression and activation of TLR4-MD-2/MyD88/NF-KB signaling pathway to exaggerate lung inflammation in vitro. Inhibition of PAI-1 may lead to novel therapeutic approaches against bacterial or LPS-induced lung inflammation.PAI-1 knockdown reduced NF-KB p65 expression after LPS stimulation, whereas PAI-1 overexpression showed the opposite result. It indicates that in the LPS-induced inflammatory response, PAI-1 promotes inflammation through the TLR4/NF-KB pathway in vitro, whereas deletion of PAI-1 resulted in decreased TLR4/NF-KB pathway activity and reduced inflammation.

Study the regulatory mechanism of PAI-1 signaling pathway in clinical diseases
Study the influence of various human viruses on the PAI-1 signaling pathway
Study the influence of carcinogenic drugs or therapies on the signal pathway of PAI-1

• Luminex Multiplex Assay
• Enzyme-linked immunosorbent assay (ELISA)
• Flow cytometry (FACS analysis) technology

Detectable targets: PTP, VPS34, UYRAG, CrkII, IRS1, MEK6, ANT, PI3K, NFκB, IRF9, IRSI-4, p50, LDHA, FIP200, RIG-1, AMBRA1, TRAF6, p53, LKB1, ULK, TRAF3, p38, SH2, TRAM, Shc, PROLC3, CAP, RIP1, p38MAPK, TRIF, Erk1, LC3I, ISGF3, TRAF5, MEK3, IRAK1, PHGDH, PDHK, MSK2, Gab-1, IRF5, ISRE, PFK, Grb2, mTOR, IRS2, Shp-2, PKR, ULK1, Bax, TBK1, MSK1, TLR3, c-Myc, VDAC, Vav, p65, Tak1